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Purpose: To assess the results of tracheal cancer patients treatment and factors inﬂuencing
prognosis.
Background: Primary malignant neoplasms of the trachea are rare. The treatment of choice
for tracheal carcinomas is resection. Radiation therapy is recommended as a part of radical
treatment or for palliation of symptoms.
Materials and methods: Between 1962 and 2006, 50 patients diagnosed with tracheal cancer
were treated at the Centre of Oncology in Krakow. The analysis focused on locoregional
recurrence-free survival (LRRFS), disease free survival (DFS) and overall survival (OS). Sur-
vival rates, univariate and multivariate analyses of prognostic factors were performed using
the Kaplan–Meier method, the log rank test and Cox’s proportional hazard method, respec-
tively.
For over 40 years, patients were treated using different modalities: surgery followed by
radiotherapy (6%), radiotherapy (78%), chemoradiotherapy (8%), and symptomatic treatment
(8%).
Results: The 5-year LRRFS was 18%, DFS was 15% and OS was 17%. gender (favoured females)
was the only prognostic factor for LRRFS. For OS, the independent prognostic factors were
performance status (favoured Karnofsky higher than 80), stage and year of start of the
treatment (later than 1988 vs. earlier – 5-year OS 20% vs. 12%).
5-year OS in the following (strongly differentiated over the time) treatment modalities
were: surgery followed by radiotherapy (66%), radiotherapy (16%), chemoradiotherapy (0%),
and symptomatic treatment (0%).
Of 44 patients treated with radiotherapy symptomatic partial response was observed in
32 patients and follow-up imaging studies revealed complete response in 5 patients, partialdiseresponse in 25, stableConclusions: Radical treatm
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Table 2 – Characteristics of patients.
Characteristics n %
Age
Median 56
Range 25–77
Sex
Female 19 38
Male 31 62
Performance status (Karnofsky)
<80 35 70
≥80 15 30
Histological subtype
Squamous cell carcinoma 24 48
Adenoid cystic carcinoma 5 10
Adenocarcinoma 6 12
Nondifferentiated 2 4
Small cell carcinoma 4 8
Ca solidum 3 6
Others, unknown 6 12
Stage
I 5 10
II 21 42
IIIA 18 36
IIIB 5 10
IV 1 2
Type of treatment
Surgery followed by radiotherapy 3 6
Radiotherapy alone 39 78
Chemoradiotherapy 4 8
Symptomatic treatment 4 8
Radiotherapy
Without radiotherapy 4 8
Pallative 20 40
Radical 26 52114 reports of practical oncology an
1. Introduction
Malignant tumors of trachea constitute a rare diagnosis
accounting for less than 0.1% of all malignancies.1 Since
there are no speciﬁc respiratory signs and symptoms of the
disease, potentially resectable and curable, the diagnosis is
considerably delayed until an advanced stage, which a priori
deteriorates the prognosis.
The published studies carried out until now allow to indi-
cate some well deﬁned prognostic factors such as histological
subtype – adenoid cystic carcinoma (ACC), early stage disease,
complete resection and negative surgical airway margins.2,3
Because there are no guidelines based on randomized clin-
ical trials, the choice of treatment modalities and optimal
sequence remains an open-ended question. In daily practice,
the most frequently applied is surgery with optional post-
operative radiotherapy with up to 52% 5-year overall survival
in ACC and 39% in SCC.2,4
Radiotherapy plays a signiﬁcant role as a part of radical
combined treatment as well as a palliative approach.5,6
As there are no randomized clinical trials conducted (due
to the low incidence of tracheal cancers) so far, we present
another retrospective data evaluating prognostic factors and
treatment outcome contributing to the knowledge about this
neoplasm.
2. Materials and methods
This analysis has been performed in the group of 50 patients
with tracheal cancer who were treated at the Centre of Oncol-
ogy in Krakow between 1962 and 2006. Characteristics of
patients are shown in Table 2. Median age was 56 years (range
25–77), 31 patients were male, 19 were female. All patients
presented symptoms preceding diagnosis of cancer, most
common of them being dyspnoea, cough and hemoptysis. A
substantial majority of diagnoses were based on very simple
diagnostic tools, e.g. bronchoscopy and chest X-ray, and only
the patients treated from the 1990s had additional chest com-
puted tomography. In all the cases diagnosis was conﬁrmed
by histology examination and the most common histological
type was squamous cell cancer observed in 48%. The distribu-
tion of all histological types is shown in Table 2.
Patients were treated using different treatment modali-
ties: surgery followed by radiotherapy (6%), radiotherapy alone
(78%), chemoradiotherapy (8%), and symptomatic treatment
(8%).
Of 46 irradiated patients, 26 were treated with radical and
20 with palliative intent. Median external beam radiother-
apy dose was 6400 cGy (range 5600–7000) and 3500 cGy (range
Table 1 – Proposal of staging system.
Stage
I – limited to trachea
II – limited to chest
IIIA – limited to chest +mediastinal lymph nodes involvement
IIIB – limited to chest + supraclavicular lymph nodes involvement
IV – metastatic diseaseYear of start of treatment
1962–1988 22 44
1989–2006 28 56
2000–4000), in radical and palliative treatment respectively,
while in brachytherapy cases it was 15Gy in two fractions.
In radical treatment, dose per fraction ranged from 180 to
200 cGy, while in palliative treatment it ranged from 300 to
400 cGy.
Radiotherapy was delivered by linear accelerator (24 pts.),
cobalt (20 pts.) and HDR brachytherapy (2 pts.).
Radiotherapy techniques changed during the period of this
analysis.
In the radical treatment two antero-posterior or three
oblique ﬁelds techniques were used in the ﬁrst phase, with
limitation of the dose to the spinal cord to 45Gy, using two
or three oblique ﬁelds in the second phase. Irradiated volume
in the ﬁrst phase included trachea with tumor and enlarged
lymph nodes, upper mediastinal lymph and/or cervical nodes
electively, in second phase tumor or tumor bed with margins
only. Until 1995 two-dimensional (2D) treatment planning was
used. From 1996 computed tomography was incorporated into
the planning system at the Centre of Oncology in Krakow.
Palliative treatment included tumor and enlarged lymph
nodes with margin, mostly in 2D treatment planning setting.Brachytherapy dose was speciﬁed at 1 cm from the axis of
the catheter.
All four patients in combined modality group (chemora-
diotherapy) received etoposid and cisplatin after radiotherapy.
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efore the year 2000 systemic treatment was used in distant
ailure cases only.
Since there is no international tracheal cancer staging sys-
em, for the purpose of this analysis we proposed the system
hown in Table 1, based on earlier reports from the Centre of
ncology in Krakow.3 About 90%of patients had tumor limited
o chest.
Majority (66%) of tumors were located in the lower third of
he trachea and on the lateral (26%) and posterior wall (18%).
.1. The statistical methods
he main endpoints of the analysis were locoregional
ecurrence-free survival (LRRFS), disease free survival (DFS)
nd overall survival (OS) rates.
Locoregional recurrence-free survival was measured from
he date of treatment to the date of locoregional recurrence
r death or last follow-up only in the group of patients who
esponded completely to the treatment or radical resection.
ocal failure was deﬁned as a failure occurring inside the
ediastinumand supraclavicular region (and/orwith invasive
rowth into neighbouring organs) and distant failure as any
ite of failure outside the mediastinum and supraclavicular
egion.
Survival was measured from resection to the date of death
r lost to follow-up.
Time to progressionwasmeasured from the date of the end
f treatment to the date of local or distant progression.
Comparison included several clinical (sex, age, perfor-
ance status, stage, grade, histological type, location of
umor, etc.) and treatment-related factors (type of treatment,
ntention of radiotherapy, radiation dose, year of start of treat-
ent). Survival rates were calculated using the Kaplan–Meier
ethod. Univariate and multivariate analyses of prognostic
actors were performed using the log rank and Cox’s propor-
ional hazard methods, respectively. P-values of less than 0.05
ere considered to indicate statistical signiﬁcance.
. Results
.1. Survival
uring a median follow-up of 9 months (range 1–136), we
bserved 47 cancer deaths. Only 3 patients were alive in Octo-
er 2008 of whom 2 were disease free.
The 5-year LRRFS rate, DFS rate and OS rate were 18%, 15%
nd 17%, respectively. Median survival for all patients was 8.7
onths (range 1–139).
The analysis (Tables 3 and 4) showed that only gender had
igniﬁcant impact on LRRFS. The risk of locoregional recur-
ence in females was less than one-third of the risk in males
29 vs. 9% 5-year LRRFS).
There were no prognostic factors inﬂuencing DFS.
In the univariate analysis, histological subtype, gender,
tage, type of treatment, year of start of treatment, perfor-
ance status, and intention of radiotherapy delivery were all
tatistically signiﬁcant prognostic factors for OS.
The 5-year overall survival of patients with adenoid cystic
arcinoma (80%) was signiﬁcantly better than that for all othertherapy 1 5 ( 2 0 1 0 ) 113–118 115
histological types (P<0.002). Two of 5 cases of adenoid cys-
tic carcinoma underwent surgery, which was combined with
radiotherapy, and three underwent radical radiotherapy. Five-
year overall survival ofmost common subtype – squamous cell
cancer – was 9%.
Females had longer overall survival than males (32 vs. 7%)
so had patients who started treatment after 1988 vs. those
treated before 1988 (20% vs. 12%).
5-Year OSs in the following treatment modalities were:
66% for surgery followed by radiotherapy, 16% for radiother-
apy alone, 0% for chemoradiotherapy, and 0% for symptomatic
treatment.
For OS (Table 4), the independent prognostic factors were
stage, performance status and year of start of the treatment.
The risk of death was more than one and a half in advanced
stage patients (Fig. 1). Patients with higher than 80 Karnof-
sky performance status and treated after 1988 had less than
one-third risk of death compared with patients in poorer per-
formance status and treated before 1988.
Of 38 evaluated patients treated with radiotherapy follow-
up imaging studies (X-ray, CT or bronchoscopy), complete
response occurred in 5 patients, partial response in 25, stable
disease in 4 and progressive disease in 4 (in 8 patients imaging
studies were not performed).
Symptomatic response assessment was performed in 38
radiotherapy patients. 32 patients (73%) had partial response,
2 had stable disease and 4 progressed.
3.2. Analysis of failure
During the follow-up, local recurrence of malignancy was
observed in 19 patients (73% of 26 evaluable patients). Local
recurrence was located inside in 5 patients and outside in 5
patients, in 9 casesdata couldnot beenobtained. In 12patients
(46%) distant failureswere observed, all of themwere chemon-
aive. In 8 cases distant failures were located in the lungs; in 3
it was found in the bones, in 2 in the liver and brain. Median
time to both local and distant recurrences was 9 months.
4. Discussion
Evidence in tracheal cancer treatment is based mostly on
small retrospective series (usually less than 300), which
enrolled patients during long (two, three decades) peri-
ods during which treatment and diagnostic modalities were
changing.7,8 This is also a limitation of the present study.
Clinical characteristics of our series of patients are sim-
ilar to that reported in literature. Majority of patients were
males and most patients were in the sixth and seventh decade
of life.3,4,9–11 Most common symptoms were dyspnoea, cough
and haemoptysis, which is in accordance with the largest
series4 studied, but in many other, it is haemoptysis that is
reported as the most common.6,9 Squamous cell cancer was
the most common histological type followed by adenoid cystic
carcinoma.10,12–14
Only 3 (6%) patients were operated, and the majority of
them were irradiated only, which can be ascribed to selection
bias. The majority of tracheal cancer patients in our region
had undergone resections in other hospitals, and frequently
they had not been referred to radiotherapy. It was shown in
116 reports of practical oncology and radiotherapy 1 5 ( 2 0 1 0 ) 113–118
Table 3 – Univariate analysis of prognostic factors (signiﬁcant bolded).
Prognostic factors 5-Year LRFS% 5-Year DFS% 5-Year OS%
Total group 18 15 17
Sex P=0.02 P=0.04
Female 29 24 32
Male 9 9 7
Age
>56 year 31 22 8
≤56 year 9 9 26
Histological subtype P=0.04
Ca planoepitheliale 11 11 9
Adenoid cystic carcinoma 33 33 80
Adenocarcinoma 0 0 17
Nondifferentiated NA NA 0
Small cell carcinoma 0 0 0
Ca solidum NA 50 33
Others, unknown 0 0 0
Localisation
1/3 upper 0 0 12.5
1/3 middle 0 0 29
1/3 lower 24 24 16
Not applicable NA NA 0
Localisation
Anterior wall 25 25 14
Posterior wall 0 0 22
Lateral wall 25 25 9
Circumferential 0 0 0
Not applicable 19 17 19
Year of start of treatment P=0.04
1962–1988 13 11 12
1989–2006 23 18 20
Type of treatment P=0.005
Surgery followed by radiotherapy 0 0 66
Radiotherapy alone 21 18 16
Chemoradiotherapy NA NA 0
Symptomatic treatment NA NA 0
Stage P=0.04
I NA NA 60
II 10 9 14
IIIA 29 14 12
IIIB NA NA 0
IV NA NA 0
Radiotherapy P=0.01
Without radiotherapy 0 0 0
Pallative 0 0 0
Radical 21 18 31
Performance status (Karnofsky) P=0.002
<80 19
≥80 21
NA – not applicable.
an epidemiological study by Honings that tracheal tumors are
commonly misclassiﬁed and undertreated.15
Therefore results of treatment are inferior to national reg-
isters and similar to reported single radiotherapy series and
to unresectable subgroup.1,6,13,16
Table 4 – 5 years multivariate analysis of prognostic factors.
Variable
LRFS Gender
OS
Stage
Performance status
Year of start of treatment9 3
21 47
Because of the lack of an international tracheal cancer
staging system, we designed one, only for the purpose of
this analysis, and the univariate and multivariate analyses
of OS found it a signiﬁcant prognostic factor. This staging
system is biased as the period analysed in the study was
Relative risk P-value
0.32 0.028
1.5 0.02
0.19 0.00006
0.24 0.0001
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Table 5 – Comparison of staging system designed by authors and designed by Bhattacharyya.17
Designed by authors Bhattacharyya proposal
Stage 5-Year OS 5-Year OS
I – limited to trachea 60% I – primary tumor conﬁned to
trachea, size <2 cm, no evidence of
regional nodal disease
52.8%
II – primary tumor conﬁned to
trachea, size >2 cm, no evidence of
regional nodal disease
70%
II – limited to chest 14% III – spread outside the trachea but
not adjacent organs of structures,
no evidence of regional nodal
disease
75%
IV – spread to adjacent organs of
structures, no evidence of regional
nodal disease
15%
IIIA – limited to chest +mediastinal
lymph nodes involvement
12% IV – evidence of regional nodal disease
IIIB – limited to chest + supraclavicular 0%
l
A
s
t
d
N
c
B
b
v
rlymph nodes involvement
IV – metastatic disease 0%
ong and diagnostic modalities changed in the meantime.
JCC criteria for lung cancer stage all tracheal tumors as
tage IV. There is another staging system proposed by Bhat-
acharyya which does not take into consideration neither
istant metastases nor location of the nodal involvement.17
evertheless, this staging system also predicts survival. The
omparison between our staging system and that proposed by
hattacharyya is shown in Table 5.
Theprognosis for adenoid cystic carcinomas is signiﬁcantly
etter than that for squamous cell tracheal cancers in the uni-
ariate analysis, which supports results of other studies.4,13,18
We found also that resection of tracheal cancer followed by
adiotherapy was associated with improved survival.4,16,19
Fig. 1 – OverallNone
Patients who started to be treatment after 1989 had better
overall survival than those who were treated earlier which can
be explained by improvement of imaging and radiation deliv-
ery methods (the use of modern radiotherapy techniques and
higher energies).
The risk of locoregional recurrence in femaleswas less than
one-third of the risk in males. This is not in agreement with
other papers,5 but patients with squamous cell tracheal can-
cers (who have worse prognosis) were more likely to be male.4In our series local relapses are one and half times more
common thandistant ones, this ratio is similar to that reported
by Gaissert, but the proportion of relapsed patients to total
tracheal patients is much higher.4 This can be explained by a
survival.
d rad
r
19. Webb BD, Walsh GL, Roberts DB, Sturgis EM. Primary tracheal118 reports of practical oncology an
higher number of patients with advanced disease compared
to other series.4
In 38 evaluable patients treated with radiotherapy,
response rate assessed by follow-up imaging studies was
73%, whereas in other studies it was heterogeneous ranging
between 26% and 73%.5,6,9,20
There were only two side effects of radiotherapy: pneu-
monitis and oesophagitis (both grade 2). The frequency and
severity of side effects of radiotherapy were very low because
of underreported side effects in retrospective studies.
Results of this study should be interpreted with caution
because of a small number of patients, retrospective design,
and time period of the study which are all important limita-
tions of the study.
5. Conclusions
Radical treatment in patients in early stage and good perfor-
mance status are correlated with improvement of survival.
Despite the fact that results of treatment are pessimistic,
radiotherapy offers symptomatic improvement.
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